Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Rev: A Release Date: 05/25/2015 IVD Cyclin E1(EP126) Intended Use: Clone EP126 Source Rabbit Monoclonal Cat # PR178-6ml RTU PR178-3ml RTU CR178-0.1ml Conc CR178-0.5ml Conc HAR178-6ml RTU HAR178-3ml RTU This antibody is intended for use to qualitatively Regulatory IVD identify Cyclin E1antigen by light microscopy in Status formalin fixed, paraffin embedded tissue sections using immunohistochemical detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper controls and must be made within the context of the patient’s clinical history and other diagnostic tests. A qualified pathologist must perform evaluation of the test. Summary and Explanation: Cyclin E1 is a member of the cyclin E family that can associate with and activate cyclin-dependent kinase Cdk2. Expression of cyclin E1 is essential for the control of the cell cycle at the late G1 and early S phase. Ubiquination by the Cul-3 pathway and Fbw7 regulatescyclin E1 levels and is critically important in normal cells. In normal cells, cyclin E1 protein expression is tightly controlled through a combination of transcriptional and proteolytic regulatory processes. However, in many types of human tumors, cyclin E1 expression is frequently dysregulated, including overexpression, non-periodic expression relative to cell division, and generation of low molecular weight (LMW) derivatives. Several studies have consistently demonstrated that Cyclin E1 is associated with disease progression or patient survival in various malignancies including carcinomas of the breast, bladder, colon, and ovary. A recent study indicated that cyclin E amplification/overexpression is responsible for trastuzumab resistance in HER2 positive breast cancer patients. Immunogen:A synthetic peptide corresponding to residues of human Cyclin E1 protein. Isotype: Rabbit IgG Reagent Provided: Concentrated format: Antibody to Cyclin E1 is diluted in antibody diluent, with 1% bovine serum albumin (BSA) and 0.05% sodium azide (NaN3). Recommended dilutions: 1:50 – 1:100.The antibody dilution and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be US Office: 538, Selby Lane, Livermore, CA- 94551 USA, Ph: +1 925-218-6939 Corporate Office:CDC Towers, 3rd Floor, B-Block, Plot 10/8, Nacharam IDA, Road #5, Nacharam, Hyderabad-76, India. Phone: 040-27015544/33,Fax:040-2701 5544 , E-Mail:[email protected]: www.pathnsitu.com determined by individual laboratory. Pre-diluted format: PathnSitu ready to use antibodies are pre tittered to optimal staining conditions. Further dilution may loose the activity and may yield to sub optimal staining. Storage Recommendations: Store at 2°-8°C. Do not use after expiration date provided on the vial. Staining Recommendations: Antigen Retrieval Solution: Use CitrateBuffer(PathnSitu Cat # PS009) as antigen retrieval solution Heat Retrieval Method: Retrieve sections under steam pressure for 15 min using PathnSitu’s MERS (Multi Epitope Retrieval System) then allow solution to cool for 10 minutes then transfer tissue sections/slides to distilled water. Primary Antibody: Cover the tissue sections with primary antibody and incubate for 30 min at room temperature when used PathnSitu PolyExcel Detection System. Detection System: Refer to PathnSitu PolyExcel detection system protocol or manufacturer’s detection kit staining protocol when used other vendor detection system. Cellular Localization: Nuclear, Cytoplasmic reactivity also observed. Positive Control: Placenta, Breast Cancer Troubleshooting: Follow the antibody specific protocol recommendations according to data sheet provided. If unusual results occur, contact PathnSitu Technical Support at 0402701 5544 or [email protected]. Limitations and Warranty: There are no warranties, expressed or implied, which extend beyond this description. PathnSitu is not liable for property damage, personal injury, or economic loss caused by this product. Bibliography: 1. Ohtsubo M, et al.: Mol Cell Biol1995, 15:2612-2624 2. Spruck C, et al.: Cancer Res 2006, 66:7355-7360 3. Keyomarsi K, et al.: N Engl J Med 2002, 347:1566-1575 4. Del Pizzo JJ, et al.: Am J Pathol1999, 155:1129-1136 5. Li JQ, et al.: Hum Pathol2001, 32:945-953 6. Nakayama N, et al.: Cancer 2010, 116:2621-2634 7. Shaye A, et al.: Breast Cancer Res Treat 2009, 115:651-659 8. Scaltriti M, et al.: ProcNatlAcadSci U S A 2011, 108:3761-3766 Cyclin E1, EP126 antibody has been created by Epitomics Inc., using Epitomics’ proprietary rabbit monoclonal antibody technology covered under Patent No.’s 5,675,063 and 7,402,409. US Office: 538, Selby Lane, Livermore, CA- 94551 USA, Ph: +1 925-218-6939 Corporate Office:CDC Towers, 3rd Floor, B-Block, Plot 10/8, Nacharam IDA, Road #5, Nacharam, Hyderabad-76, India. Phone: 040-27015544/33,Fax:040-2701 5544 , E-Mail:[email protected]: www.pathnsitu.com